Aspera Biomedicines

Name

Aspera Biomedicines

Legal name

Aspera Biomedicines

Website

https://asperabiomedicines.com

Company type

Private

Founded year

2021

Operating status

Operating

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Cancer stem cell therapy
• ADAR1 inhibitor drugs
• Oncology drug development
• Microgravity research platform
• Clinical-stage biotechnology

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Pre-commercial stage company. Revenue will come from sales of Rebecsinib and future pipeline products upon FDA approval. Rebecsinib targets myelofibrosis and acute myeloid leukemia with potential expansion across 20+ ADAR1-overexpressing malignancies.
2. Partnership and Licensing Deals: Strategic partnerships with pharmaceutical companies for co-development, milestone payments, and licensing royalties. Currently collaborating with pharmaceutical partners including potential deals for ADAR1 inhibitor development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Aspera Biomedicines develops Rebecsinib, a first-in-class ADAR1 inhibitor (FDA IND #153126) that targets cancer stem cells to treat myelofibrosis, acute myeloid leukemia, and potentially 20+ ADAR1-overexpressing cancers. The company supports this pipeline with a space-accelerated drug discovery platform that uses microgravity research aboard the ISS to compress cancer evolution studies and optimize therapeutic dosing.

Product overview

Aspera Biomedicines is a space-accelerated biotechnology company developing first-in-class cancer therapies. The company's core offering is Rebecsinib, a first-in-class ADAR1 inhibitor (IND-cleared, entering Phase 1/2 clinical trials for myelofibrosis and acute myeloid leukemia), supported by a space-accelerated drug discovery platform that uses ISS-based nanobioreactors and microgravity research to compress cancer research timelines. The platform has generated three NASA ISS missions focusing on Rebecsinib optimization and ADAR1p150 protein crystallization.

Differentiator

Problem solved

Functional benefit

Products and services

• Rebecsinib First-in-class ADAR1 inhibitor (IND #153126) targeting cancer stem cells for treatment of myelofibrosis (MF) and acute myeloid leukemia (AML), with potential expansion across 20+ ADAR1-overexpressing cancers. Designed to reverse ADAR1p150 activation to restore immune visibility and prevent cancer relapse at the root.

Quantifiable outcome

• Cancer evolution compressed 7x faster in microgravity, enabling research acceleration
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and major.

• Axiom SpacecoreImplementation/ SI/ Consulting PartnerHouston-based aerospace company specializing in commercial space infrastructure and human spaceflight. Designs and operates private missions to the ISS and is developing the world's first commercial space station. Conducts Aspera's drug experiments aboard Axiom missions (Ax-2, Ax-3, Ax-4) using astronaut-conducted research protocols.
• RedwirecoreTechnology or IntegrationSpace infrastructure company providing PIL-BOX (Pharmaceutical In-space Laboratory) technology for Aspera's ISS experiments. PIL-BOX supports pharmaceutical research including protein crystallization and cancer therapy investigations with 43 units already flown to the ISS.
• Space TangocoreTechnology or IntegrationSpace manufacturing and research company specializing in automated payloads for microgravity experiments. Provides CubeLabs - modular, robotic systems for the ISS - that have flown over 300 experiments since 2016 for biomedicine research.
• SpaceXcoreImplementation/ SI/ Consulting PartnerLeading aerospace manufacturer and space transportation company. Provides Dragon spacecraft for cargo and crew missions to the ISS, serving as launch provider for Aspera's experiments including Rebecsinib and ADAR1p150 crystallization missions aboard CRS and Crew missions.
• Tempus AImajorStrategic or Co-development PartnerPrecision medicine company leveraging AI to analyze clinical and molecular data for oncology. Partners with Aspera to accelerate drug discovery through genomic sequencing, AI-driven insights, and real-world evidence platforms with database of over 6 million patient records.
• National Institutes of Health (NIH)majorStrategic or Co-development PartnerPrimary U.S. federal agency for biomedical research funding over $45 billion annually in grants. Supports Aspera's cancer stem cell research and ADAR1 studies through research grants and scientific collaboration.
• California Institute for Regenerative Medicine (CIRM)majorStrategic or Co-development PartnerCalifornia state agency funding stem cell research with over $8.5 billion in grants by 2025. Supports therapies for chronic diseases including cancer, advancing clinical trials and research infrastructure.
• Bristol Myers SquibbmajorStrategic or Co-development PartnerMajor pharmaceutical company collaborating with Redwire on cancer therapy research aboard the ISS. Part of broader industry partnerships advancing drug development in microgravity.
• Eli LillymajorStrategic or Co-development PartnerMajor pharmaceutical company partnering with Redwire on disease research aboard the ISS. Collaborating on pharmaceutical research including treatments for cancer, osteoporosis, and obesity.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AbbVie: Global oncology and immunology major that acquired Stem Centrx (a cancer stem cell company co-founded by Aspera board director Scott Dylla). Comparable as a benchmark acquirer and incumbent in the CSC/oncology space Aspera targets.
• Schrödinger: Physics-based computational drug-discovery platform with a growing internal pipeline and partnerships across pharma. Comparable as a platform-driven drug-discovery peer with a similar 'engine + pipeline' business model.
• Recursion Pharmaceuticals: AI-driven drug-discovery platform company with a clinical-stage oncology pipeline. Comparable as a platform-led biotech using a differentiated discovery engine to compress timelines, analogous to Aspera's space-accelerated thesis.
• Celgene: Acquired Aspera CEO Raghu Saripalli's prior company Impact Biomedicines and commercialized Inrebic (fedratinib) in myelofibrosis — the same indication Aspera is now pursuing with Rebecsinib. Highly comparable for deal precedent, indication overlap, and competitive dynamics.
• Eli Lilly: Major pharmaceutical company also collaborating with Redwire on ISS-based disease research including oncology. Comparable as a deep-pocketed incumbent operating in the same microgravity-research ecosystem and as a likely strategic-partner or competitor for Aspera's pipeline.
• Bristol Myers Squibb: Major oncology pharmaceutical company partnering with Redwire on cancer therapy research aboard the ISS. Directly comparable as both a potential out-licensing partner for Rebecsinib and a likely competitor in ADAR1-adjacent hematology/oncology indications.

Emerging players

• Wave Life Sciences: Clinical-stage RNA-editing and antisense oligonucleotide developer, including programs targeting ADAR-mediated RNA editing. Comparable as a direct peer pursuing the same ADAR biology from a nucleic-acid modality angle.
• ProQR Therapeutics: RNA-therapeutics company developing antisense oligonucleotide and RNA-editing platforms. Comparable as an emerging player operating in RNA-biology drug discovery with platform-level ambitions similar to Aspera's space-accelerated approach.
• Korro Bio: Clinical-stage biotech developing RNA-editing therapeutics, including ADAR-based approaches. Most direct emerging competitor in the ADAR1/RNA-editing biology space that Aspera's lead asset targets.

Direct peers

• Tempus AI: Precision-medicine and AI-driven drug-discovery partner of Aspera. Comparable as a data/AI-enablement peer working at the intersection of genomics, oncology pipelines, and pharmaceutical R&D acceleration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aspera Biomedicines